You should not take Ozempic if you have a personal or family history of medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2
Results vary, but many patients begin seeing progress within the first few weeks when following a structured plan
Lastly, the future positioning of dual GIP/GLP-1RA against GLP-1RA in the treatment landscape of T2D needs to be better defined
Compare that to typical discontinuation rates of 5% to 10% with GLP-1 receptor agonists
The FDA approval is only for people with obesity, but it could help those with sleep apnea get Medicare coverage, which doesnt cover drugs just for weight loss, according to a report
GLP-1s are expected to become the biggest class of drugs in history, with annual sales projected to top $100 billion over the next five years, according to a September 2025 note by Morgan Stanley